Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

Current Medical Research and Opinion

Volumn 29, Issue 9, 2013, Pages 1075-1082

  Goldberg, Stuart L ^a   Chen, Lei ^b   Guerin, Annie ^c   MacAlalad, Alexander R ^c   Liu, Nathan ^c   Kaminsky, Michael ^c   Ericson, Solveig G ^b   Wu, Eric Q ^c  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ANALYSIS GROUP   (United States)

Author keywords

Chronic myelogenous leukemia; Progression free survival; Quantitative real time polymerase chain reaction; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESSENGER RNA;

ADULT; ARTICLE; BLAST CELL CRISIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MONITORING; OUTCOME ASSESSMENT; PHYSICIAN; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; QUANTITATIVE POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; BLAST CRISIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84882784105     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.812034     Document Type: Article

References (20)

1. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-102
2. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-42
3. Palandri F, Iacobucci I, Soverini S, et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: Importance of a stable molecular response. Clin Cancer Res 2009;15:1059-63
4. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32
5. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13:6136-43
6. Etienne G, Nicolini NE, Dulucq S, et al. Achieving a complete molecular remission under imatinib therapy is associated with a better outcome in chronic phase chronic myeloid leukaemia patients on imatinib frontline therapy. ASH Annual Meeting Abstracts 2012;120:3754
7. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20
8. Radich JP, Oehler V. Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors. J Natl Compr Canc Netw 2007;5:497-504
9. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia (v 4.2013). Available at: Http://www.nccn.org/professionals/physician-gls/pdf/cml.pdf [Last accessed 24 May 2013]
10. European LeukemiaNet. Recommendations from the European LeukemiaNet for the Management of Chronic Myeloid Leukemia (CML) (Update 2010). Available at: Http://www.leukemia-net.org/content/leukemias/cml/recommendations/e8078/ infoboxContent8096/PocketCard-2010-final.pdf [Last accessed 12 September 2012]
11. Chen L, Guerin A, Xie J, et al. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: A chart review analysis. Curr Med Res Opin 2012;28:1831-9
12. Jackson J, Chen L, Sail KR, et al. Monitoring patterns and subsequent outcomes among patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) treated with imatinib in a community setting. ASH Annual Meeting Abstracts 2012;120:2066
13. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008;13(Suppl 2):19-21
14. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-32
15. Wang L, Knight K, Lucas C, et al. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006;91:235-9
16. Press RD, Willis SG, Laudadio J, et al. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114:2598-605
17. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
18. Branford S, Yeung DT, Prime JA, et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: Implications for monitoring and management. Blood 2012;119:4264-71
19. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32
20. Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases. Am J Hematol 2004;76:275-8